LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

• Market Cap: €231.13M
• Dividend Yield: 1.71%
• Average Volume (3M): 52.61K
• Price to Earnings (P/E): 34.9
• Beta (1Y): 0.24
• Revenue Growth: -1.19%
• EPS Growth: -54.66%
• Country: ES
• Employees: 1,331
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 82,219,240
• 10 Day Avg. Volume: 54,529
• 30 Day Avg. Volume: 52,611
• PEG Ratio: 2.30
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 0.59
• P/FCF Ratio: 18.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: €3.00 ▲(0.33% Upside)

The overall stock score is driven primarily by strong financial performance, which indicates robust revenue and profit growth, solid balance sheet, and healthy cash flow. However, technical analysis suggests potential short-term weakness, and the valuation indicates the stock may be overvalued. The absence of earnings call and corporate events data limits additional insights.

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre (RJF) is a Spanish pharmaceutical and healthcare company that specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical products, including prescription medicines, over-the-counter products, and healthcare solutions. Operating primarily in the sectors of pharmaceuticals, biotechnology, and healthcare, RJF focuses on therapeutic areas such as oncology, pain management, and infectious diseases. The company is committed to innovation and quality in its offerings, leveraging state-of-the-art technology and research to meet the evolving needs of patients and healthcare professionals.

How the Company Makes Money

Laboratorio Reig Jofre generates revenue through the sale of its pharmaceutical products, which include both prescription medications and over-the-counter drugs. The company operates on a business model that encompasses direct sales to hospitals, pharmacies, and healthcare providers, as well as partnerships with other pharmaceutical companies for the distribution of its products. Additionally, RJF may engage in licensing agreements and collaborations for research and development, contributing to its revenue streams. The company's focus on innovative therapies and expanding its product portfolio in response to market demand also plays a significant role in driving sales and earnings.

LABORATORIO REIG JOFRE Financial Statement Overview

Summary

LABORATORIO REIG JOFRE displays robust financial performance with consistent revenue and profit growth. The balance sheet is strong with manageable leverage and solid equity. Cash flow generation is healthy, providing ample liquidity for operations and investments. The company demonstrates strong financial health and growth potential in the Pharmaceuticals industry.

Income Statement

The company has demonstrated a strong revenue growth trajectory, with a notable increase from €316.09M to €338.90M year-over-year, marking a 7.22% growth rate. Gross Profit Margin is healthy at 57.73%, indicating efficient cost management. The Net Profit Margin improved to 3.06%, reflecting better profitability. EBIT and EBITDA margins are stable at 3.72% and 10.68% respectively, though room for improvement remains.

Balance Sheet

The Debt-to-Equity ratio is reasonable at 0.27, indicating a balanced leverage. Return on Equity is moderate at 4.85%, suggesting efficient asset utilization. The company maintains a good Equity Ratio of 62.06%, supporting financial stability. Overall, the balance sheet reflects sound financial health with manageable debt levels.

Cash Flow

Operating Cash Flow has increased significantly to €31.34M, showcasing strong cash-generating ability. Free Cash Flow to Net Income ratio is 1.02, indicating effective cash management. Free Cash Flow grew by 66.37%, reflecting improved financial flexibility. The company is well-positioned to meet its short-term obligations and invest in growth opportunities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	415.66M	338.89M	316.09M	271.15M	236.23M	230.08M
Gross Profit	244.01M	195.68M	176.89M	69.58M	144.98M	140.40M
EBITDA	38.46M	36.18M	33.89M	30.44M	24.66M	24.31M
Net Income	8.86M	10.38M	9.41M	8.11M	5.09M	5.67M
Balance Sheet
Total Assets	357.56M	344.85M	330.55M	321.19M	324.98M	317.15M
Cash, Cash Equivalents and Short-Term Investments	10.84M	16.08M	6.36M	6.88M	5.16M	11.69M
Total Debt	67.06M	58.52M	53.49M	61.24M	67.38M	57.02M
Total Liabilities	141.17M	130.90M	126.29M	126.64M	136.46M	132.67M
Stockholders Equity	216.42M	213.97M	204.35M	194.63M	188.59M	184.55M
Cash Flow
Free Cash Flow	0.00	10.56M	6.34M	4.75M	-5.26M	6.55M
Operating Cash Flow	0.00	31.34M	19.11M	16.15M	14.50M	22.50M
Investing Cash Flow	0.00	-31.96M	-12.88M	-12.72M	-34.70M	-30.70M
Financing Cash Flow	0.00	5.59M	-7.16M	-2.04M	13.67M	9.62M

LABORATORIO REIG JOFRE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Negative. The current price of 2.99 is above the 20-day moving average (MA) of 2.95, above the 50-day MA of 2.92, and above the 200-day MA of 2.88, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	77 Outperform	€1.37B	12.96	14.89%	4.06%	11.04%	8.29%
RJF	65 Neutral	€231.13M	34.85	2.03%	1.71%	-1.19%	-54.66%
ROVI	65 Neutral	€2.98B	22.67	20.70%	1.70%	-9.39%	-25.92%
ALM	61 Neutral	€2.61B	121.80	1.45%	1.33%	13.32%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORY	48 Neutral	€272.44M	-52.51	-4.53%	―	―	-2.02%
ATRY	43 Neutral	€241.61M	-9.82	-9.43%	―	15.90%	37.03%